Replies to post #421 on Equity Field Notes from temporal sources

[DanWebzster]

SELB is a clinical stage biotech now focusing on immunogenicity with 2 product lines:

1) A ph2 Gout drug

2) ImTorr a gene therapy platform intended to induce Dendritic cells to generate T-cells with enhanced selectivity.

ImTorr is expected to reach the clinic EOY/20. The first target for ImTorr will be Pompe. But, AVRO seems to be well ahead of them.

SEL-212's Ph2 disappointed the market with mixed results. Despite questions about statistical sig and without clear POC, management has already decided to push ahead with Ph3.

FY19 70.6M was burned.

This will have to trade well below cash during tax loss season for me to consider it for a trade.

[DanWebzster]

VYNE is the name of the Dermatology therapeutics concern that formed when MNLO & FOMX combined.

It markets 2 products:

1) Amzeeq has grown scips 20% since the beginning of the April shutdown. It is a treatment for cystic acne.

2) Zilxi, the rosacea treatment has improving health plan coverage.

Potential future catalysts include potential ex-US partnerships and milestones for pipeline asset FCD105 ( a treatment for Acne Vulgaris).

Earnings are 2/5/8/11. I'd be curious to hear the next earnings scheduled 11/4/20.